Evaluation of the effect of toripalimab and neoadjuvant chemotherapy in treating locally advanced resectable oral squamous cell carcinoma

doi:10.19438/j.cjoms.2025.05.012

Abstract

Abstract: PURPOSE: To evaluate the effectiveness of combining toripalimab with neoadjuvant chemotherapy for treating locally advanced resectable oral squamous cell carcinoma (OSCC). METHODS: A total of 98 patients with OSCC who received treatment in Qingdao Central Hospital, Rehabilitation University from January 2020 to January 2022 were randomly divided into experimental group and control group, with 49 cases in each group. The control group was treated with neoadjuvant chemotherapy consisting of albumin-bound paclitaxel and cisplatin, while the experimental group additionally received toripalimab on the basis of the control treatment. After 3 weeks of treatment, radical surgery was performed. The clinical efficacy at 6 months post-surgery, as well as immune function inflammatory cytokine levels, tumor markers, and quality of life before and after treatment were compared between the two groups using the Oral Health Impact Profile (OHIP) and University of Washington Quality of Life (UW-QOL) scales. A 2-year follow-up was conducted to record overall survival (OS) and survival rates. RESULTS: The experimental group showed improved clinical efficacy and immune function compared to the control group, with significantly lower inflammatory cytokine levels and tumor markers. Additionally, the experimental group exhibited a higher quality of life post-treatment (P<0.05). Follow-up results demonstrated that the experimental group had higher average OS and survival rates compared to the control group(P<0.05). CONCLUSIONS: Toripalimab in combination with neoadjuvant chemotherapy shows effectiveness in treating locally advanced resectable oral squamous cell carcinoma, enhancing clinical outcomes and survival rates.

Key words: Neoadjuvant chemotherapy, Toripalimab, Albumin-bound paclitaxel, Cisplatin, Oral squamous cell carcinoma, Quality of life

CLC Number:

R739.8

Chen Wenjian, Zhang Gong, Ji Yenan, Song Lei. Evaluation of the effect of toripalimab and neoadjuvant chemotherapy in treating locally advanced resectable oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2025, 23(5): 502-507.

References

[1] Luo G, Wang S, Lu W, et al.Application of metabolomics in oral squamous cell carcinoma[J]. Oral Dis, 2024, 30(6): 3719-3731.
[2] Leng XF, Daiko H, Han YT, et al.Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma[J]. Ann N Y Acad Sci, 2020, 1482(1): 213-224.
[3] Wei T, Ti W, Song Q, et al.Study of PD-1 inhibitors in combination with chemoradiotherapy/chemotherapy in patients with esophageal squamous carcinoma[J]. Curr Oncol, 2022, 29(5): 2920-2927.
[4] Chen B, Liu S, Zhu Y, et al.Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab[J]. Nat Commun, 2024, 15(1): 1919.
[5] 杨学宁, 吴一龙. 实体瘤治疗疗效评价标准-RECIST[J]. 循证医学, 2004, 4(2): 85-90,111.
Yang XN, Wu YL.RECIST-New guidelines to evaluate the response to treatment in solid tumors[J]. The Journal of Evidence-Based Medicine, 2004, 4(2): 85-90,111.
[6] Kurzrock R, Gurski LA, Carlson RW, et al.Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals[J]. Ann Oncol, 2019, 30(10): 1647-1652.
[7] 姬爱平, 杨佑成. 口腔科学[M]. 北京: 北京大学医学出版社, 2008: 46-48.
Ji AP, Yang YC.Stomatology [M]. Beijing: Peking University Medical Press, 2008: 46-48.
[8] Xu Q, Wang SM, Liu YH, et al.Comparison between the radial forearm and groin soft tissue free flaps for reconstruction in patients with oral cavity cancer: a quality of life analysis[J]. Int J Oral Maxillofac Surg, 2022, 51(10): 1289-1295.
[9] Paré A, Joly A.Oral cancer: risk factors and management[J]. Presse Med, 2017, 46(3): 320-330.
[10] Ren G, Ju H, Wu Y, et al.A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma[J]. Int J Hyperthermia, 2021, 38(1): 939-947.
[11] 赵睿娟, 李正霞, 张芳芳. 口腔鳞状细胞癌患者首次根治性手术治疗后的生存情况及其影响因素分析[J]. 实用癌症杂志, 2022, 37(9): 1554-1556.
Zhao RJ, Li ZX, Zhang FF.Analysis of survival factors of oral squamous cell carcinoma[J]. The Practical Journal of Cancer, 2022, 37(9): 1554-1556.
[12] Okano S, Homma A, Kiyota N, et al.Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck[J]. Jpn J Clin Oncol, 2021, 51(2): 173-179.
[13] de Oliveira TB, Marta GN, de Castro Junior G, et al. Induction chemotherapy for advanced oral cavity cancer[J]. Curr Oncol Rep, 2021, 23(11): 129.
[14] 王红玲, 岳恺, 吴延升, 等. PD-1单抗联合化疗新辅助治疗局部晚期可切除口腔鳞癌的Ⅱ期临床研究[J]. 中华耳鼻咽喉头颈外科杂志, 2024, 59(4): 335-342.
Wang HL, Yue K, Wu YS, et al.PhaseⅡclinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2024, 59(4): 335-342.
[15] Liu J, Chen Z, Li Y, et al.PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy[J]. Front Pharmacol, 2021, 12: 731798.
[16] Jiang X, Ji Z, Li P, et al.Long term survival following cryoablation with adjuvant Toripalimab for anorectal malignant melanoma: a case report[J]. Front Oncol, 2025, 15: 1465645.
[17] 魏小丽, 任超, 王风华, 等. 抗PD-1抗体特瑞普利单抗治疗难治性恶性实体瘤的I期研究[J]. 癌症, 2021, 40(10): 426-435.
Wei XL, Ren C, Wang DH, et al.Phase I study of the anti-PD-1 antibody triplizumab in the treatment of refractory malignant solid tumors[J]. Chinese Journal of Cancer, 2021, 40(10): 426-435.
[18] Zinner R, Johnson JM, Tuluc M, et al.Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer[J]. J Clin Oncol, 2020, 38(15 suppl): 6583.
[19] Smith ER, Huang M, Schlumbrecht MP, et al.Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel[J]. Front Oncol, 2022, 12: 907520.
[20] Coschi CH, Juergens RA.Overcoming resistance mechanisms to immune checkpoint inhibitors: leveraging the anti-tumor immune response[J]. Curr Oncol, 2023, 31(1): 1-23.
[21] Dai Z, Li N, Wang J, et al.Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov[J]. Front Pharmacol, 2023, 14: 1212813.
[22] 刘芳, 董红雨, 王叶琳, 等. 特瑞普利联合新辅助化疗对局部晚期食管癌患者程序性死亡受体1、程序性死亡受体配体1表达水平及术后生存情况的影响[J]. 中国卫生检验杂志, 2023, 33(5): 520-523.
Liu F, Dong HY, Wang YL, et al.Effects of Toripali combined with neoadjuvant chemotherapy on PD-1, PD-L1 levels and postoperative survival in patients with locally advanced esophageal cancer[J]. Chinese Journal of Health Laboratory Technology, 2023, 33(5): 520-523.
[23] 赵佳, 慕腾, 张国庆, 等. 特瑞普利单抗联合化学治疗对局部晚期食管鳞癌患者免疫功能及预后的影响[J]. 成都医学院学报, 2024, 19(4): 598-602.
Zhao J, Mu T, Zhang GQ, et al.Effect of Toripalimab combined with chemotherapy on immune function and prognosis in patients with locally advanced esophageal squamous cell carcinoma[J]. Journal of Chengdu Medical College, 2024, 19(4): 598-602.